Saturday 7 November 2026
Export RGNX’s income statement to Excel — free account
REGENXBIO Inc.
RGNX Healthcare Biotechnology
REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024.
- Revenue
- −69.2%
- EPS
- +48.0%
- Free cash flow
- +168.1%
Quarter to September 2026, against a year earlier
7.56
0.18
+2.44%
Follow RGNX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 2 | 5 |
+8 more TTM periods Free account |
| (113.24%) | (137.63%) | (196.43%) | (107.00%) | ||
| (35.36%) | (40.60%) | (69.65%) | (42.19%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(50.27%) | (77.95%) | (133.47%) | (72.33%) | |
Average Days of Receivables |
20.24 | 223.32 | 41.72 | 56.49 | |
Free Cash Flow per Share |
(2.37) | (4.73) | (4.51) | (2.45) | |
Free Cash Flow |
(154.80) | (249.67) | (236.40) | (126.38) | |
Capital Expenditures |
(2.70) | (2.99) | (2.62) | (2.41) | |
| Other line items | |||||
Cash ROIC |
(38.77%) | (140.65%) | (137.79%) | (37.97%) | |
Accounts Receivable Turnover |
9.08 | 2.75 | 6.22 | 7.28 | |
Accounts Payable Turnover |
1.07 | 1.28 | 1.39 | 0.92 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
256.50 | 238.73 | 277.08 | 384.06 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
152.07% | 131.32% | 264.80% | 133.95% | |
Selling, General and Administrative Expense of Revenue |
55.80% | 49.03% | 95.45% | 48.62% | |
Share Based Compensation of Revenue |
22.20% | 20.08% | 39.45% | 20.28% | |
Interest Coverage |
(4.06) | (3.91) | (5.69) | (3.58) | |
Operating CF/Net income |
0.87 | 1.26 | 0.81 | 0.64 | |
Depreciation/Fixed assets |
0.00 | 0.17 | 0.15 | 0.15 | |
Capex/Depreciation |
0.00 | (0.18) | (0.17) | (0.15) | |
Revenue per Share |
2.36 | 3.30 | 1.68 | 3.30 | |
Operating CF per Share |
(2.33) | (4.67) | (4.46) | (2.40) | |
Capex per Share |
(0.04) | (0.06) | (0.05) | (0.05) | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.01 |
Columns are period end dates · fundamentals updated 6 Nov 2026